Valuation: H. Lundbeck A/S

Capitalization 3.88TCr 601.8Cr 519.05Cr 475.47Cr 449.29Cr 828.29Cr 58TCr 849.14Cr 5.67TCr 2.21TCr 27TCr 2.26TCr 2.21TCr 96TCr P/E ratio 2026 *
8.91x
P/E ratio 2027 * 8.72x
Enterprise value 4.29TCr 665.39Cr 573.9Cr 525.72Cr 496.77Cr 915.82Cr 64TCr 938.87Cr 6.27TCr 2.44TCr 30TCr 2.5TCr 2.44TCr 1,05900Cr EV / Sales 2026 *
1.67x
EV / Sales 2027 * 1.51x
Free-Float
30.76%
Yield 2026 *
3.67%
Yield 2027 * 3.75%
1 day+2.17%
1 week-0.72%
Current month-4.20%
1 month-5.52%
3 months+2.70%
6 months-6.93%
Current year-4.82%
1 week 39.68
Extreme 39.68
41.88
1 month 39.68
Extreme 39.68
45.76
Current year 35.3
Extreme 35.3
47.04
1 year 32.74
Extreme 32.74
47.78
3 years 27.2
Extreme 27.2
49.38
5 years 23.3
Extreme 23.295
49.38
10 years 23.3
Extreme 23.295
49.38
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 66 25/03/2015
Director/Board Member 60 20/03/2018
Change 5d. change 1-year change 3-years change Capi.($)
+2.17%-0.72%+14.49%+4.00% 601.8Cr
-1.81%+3.70%+4.89%+91.59% 9.16TCr
+0.30%+9.76%+30.23%+133.18% 4.69TCr
-0.35%-0.70%-6.27%+317.65% 2.32TCr
+1.39%-2.45%-8.18%-23.95% 823.44Cr
+0.07%-10.22%-25.42%-27.75% 775.77Cr
+0.28%-3.06%-4.37%-34.09% 704.32Cr
-0.69%+1.71%-5.34%+11.21% 529.09Cr
-2.23%+2.05%+24.98%+25.73% 372.81Cr
+1.03%-2.96%-4.84%-15.89% 360.18Cr
Average +0.02%-0.01%+2.02%+48.17% 2.03TCr
Weighted average by Cap. -0.69%+4.77%+7.67%+105.63%

Financials

2026 *2027 *
Net sales 2.57TCr 399.43Cr 344.51Cr 315.59Cr 298.21Cr 549.76Cr 39TCr 563.6Cr 3.76TCr 1.46TCr 18TCr 1.5TCr 1.47TCr 64TCr 2.57TCr 399.31Cr 344.4Cr 315.49Cr 298.12Cr 549.59Cr 39TCr 563.42Cr 3.76TCr 1.46TCr 18TCr 1.5TCr 1.47TCr 64TCr
Net income 445.68Cr 69Cr 60Cr 55Cr 52Cr 95Cr 6.7TCr 98Cr 651.17Cr 253.58Cr 3.15TCr 259.53Cr 253.99Cr 11TCr 480.53Cr 75Cr 64Cr 59Cr 56Cr 102.63Cr 7.22TCr 105.21Cr 702.09Cr 273.41Cr 3.4TCr 279.82Cr 273.85Cr 12TCr
Net Debt 409.82Cr 64Cr 55Cr 50Cr 47Cr 88Cr 6.16TCr 90Cr 598.78Cr 233.18Cr 2.9TCr 238.64Cr 233.56Cr 10TCr -3.01Cr -46.67L -40.26L -36.88L -34.85L -64.24L -45Cr -65.86L -4.39Cr -1.71Cr -21Cr -1.75Cr -1.71Cr -74Cr
Logo H. Lundbeck A/S
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
20/26/20 41.08 kr +2.29% 1,26,013
19/26/19 40.16 kr +0.05% 7,25,007
18/26/18 40.14 kr -3.00% 16,63,465
13/26/13 41.38 kr -0.43% 6,53,655
12/26/12 41.56 kr -1.75% 22,11,487
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
40.16DKK
Average target price
47.21DKK
Spread / Average Target
+17.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HLUN B Stock